89bio, Inc.

NasdaqGM ETNB

89bio, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -2.56

89bio, Inc. Price to Earnings Ratio (P/E) is -2.56 on January 14, 2025, a 56.69% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

89bio, Inc. 52-week high Price to Earnings Ratio (P/E) is -2.56 on January 14, 2025, which is 0.00% below the current Price to Earnings Ratio (P/E).
89bio, Inc. 52-week low Price to Earnings Ratio (P/E) is -7.34 on March 04, 2024, which is -187.20% below the current Price to Earnings Ratio (P/E).
89bio, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.97.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: ETNB

89bio, Inc.

CEO	Mr. Rohan Palekar
IPO Date	Nov. 11, 2019
Location	United States
Headquarters	142 Sansome Street
Employees	70
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Key trends

Past 5 years